Jennifer Lill, Pharm D
About Jennifer Lill, Pharm D
Jennifer Lill, Pharm D, is the Director of Headquarters (Global) Medical Affairs, Immuno-Oncology, Life Cycle Management at Bristol-Myers Squibb and also serves as Executive Director of Medical Affairs at Seattle Genetics.
Current Executive Roles
Jennifer Lill serves as the Executive Director of Medical Affairs at Seattle Genetics. Additionally, she holds the position of Director, Headquarters (Global) Medical Affairs, Immuno-Oncology, Life Cycle Management at Bristol-Myers Squibb. Her roles involve leading medical affairs teams and overseeing strategic initiatives within the oncology and immunology sectors.
Previous Experience in Medical Affairs and Clinical Development
Jennifer Lill has held numerous leadership positions in medical affairs and clinical development. Her previous roles include Vice President – Medical Affairs at Dendreon Pharmaceuticals, Vice President – Medical Affairs and Clinical Development at Spectrum Pharmaceuticals, and Vice President – Medical Affairs at Cell Therapeutics, Inc. She has also served in various director-level positions at Bayer HealthCare Pharmaceuticals and as a clinical pharmacist and assistant professor at University of Washington and University of Utah.
Education and Fellowships in Clinical Pharmacology
Jennifer Lill has an extensive educational background in pharmacy and clinical pharmacology. She earned her PharmD from the University of Michigan and has completed multiple fellowships. These include a Fellowship in Clinical Pharmacokinetics from the University of Washington, a Fellowship in Clinical Pharmacology from Mayo Graduate School of Medicine, and a Pharmacy Practice Residency from Mayo Medical Center.
Leadership in Oncology Product Launches
Throughout her career, Jennifer Lill has been instrumental in the successful launch of several oncology products in U.S. and European markets. Her experience includes managing Phase 1-4 clinical trials, navigating regulatory environments, and implementing life cycle management plans for oncology and immunologic therapies. She has a notable achievement in expanding the Zevalin® label through FDA negotiations.
Team Development and Organizational Success
Known for her ability to develop high-performing medical affairs departments, Jennifer Lill has played a critical role in revitalizing teams and enhancing productivity, especially post-acquisitions or mergers. She has sustained open lines of communication with both internal and external stakeholders, ensuring long-term organizational success and the effective execution of complex medical strategies.